Clinical Trial Update: Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating camrelizumab plus apatinib with intensity-modulated radiotherapy for resectable hepatocellular carcinoma with portal v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Yongyi Zeng | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING